The Italian court ordered the analysis of anti-Covid vaccines with messenger RNA after the complaint of a person subject to the vaccination obligation to use his profession.
An Italian court arrested by an individual opposed to anti-Covid vaccination has ordered laboratory analysis of messenger RNA (mRNA) vaccines, we learned on Saturday from the plaintiff’s lawyer.
The court in Pesaro, near San Marino (east), ordered an expert to identify the contents of Moderna and Pfizer/BioNTech messenger RNA anti-Covid vaccines. These analyzes will be carried out in September, said the lawyer Nicoletta Morante.
According to him, it is “a first in Italy, and maybe in Europe”.
Find out which proteins are in the vaccine
The complainant, who had previously contracted the disease, is a fifty-year-old who works mainly in education, and whose activity in Italy is subject to the obligation of vaccination. Refractory, he is subject to administrative sanctions, according to Me Nicoletta Morante.
In addition to “he asked to establish if the vaccination of people who have recovered from Covid satisfies the good management of medicine”, he wants to know which proteins are in these vaccines and if they contain “excipients for non-human or hazardous use. for health,” according to a summary of the complaint.
The messenger RNA treatment allows the cells to multiply the proteins present in the virus – the “antigens” – to train the immune system to recognize and neutralize it.
12 billion doses were administered
In support of the civil complaint presented to Pesaro, the lawyer made the opinion of a medical researcher, presented as an independent virologist, who believed that the mRNA vaccines did not fulfill the protective function for which they were injected. . These vaccines, he wrote in the complaint, “do not have the declared functional conformation” and the immune response they cause is “ineffective”.
According to the WHO, more than 12 billion doses of Covid vaccines have been given worldwide and 60% of the population has received two doses.